Frontlight ResearchEarly access
Active, not recruitingPhase 3
MAD Trial: Myopia Atropine Dose
Key facts
- Who runs it
- Erasmus Medical Center
- Where
- Netherlands21 sites in 1 countryChoose a country to see its sites
- Status
- Active, not recruiting
- Phase
- Phase 3
- People taking part
- 550 people, planned
- Started
- 19 Dec 2022
- Expected to end
- 24 Apr 2029
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Atropine Ophthalmic 0.05%
- Atropine Ophthalmic 0.5%
- Record updated
- 14 September 2026
Who can take part
- Age
- 6 years to 11 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 16 criteriaShow less
Who can take part
- Children aged 6 to ≤ 11 years with bilateral myopia
- Onset of myopia ≥ 4 years of age
- History of progression
- SER of at least -1.00D and no greater than -6.00D in each eye measured using cycloplegic auto refraction
- Intraocular pressure < 21 mm Hg in each eye
- Distance vision correctable to at least 0.1 Log MAR (logarithm of the minimum angle of resolution) in each eye
Who cannot take part
- Chronic use of topical or systemic antimuscarinic/anticholinergic medications in the 21 days prior to screening, and/or anticipated need for chronic use over the duration of the study (i.e., more than 7 consecutive days in 1 month or more than a total of 30 days in 1 year)
- Chronic use (more than 3 days a week) of topical ophthalmological medication (prescribed or over the counter) other than the assigned study medication. The use of artificial tears is allowed but not in the 1 hour before or after the administration of the study medication
- The anticipated need to use chronic ophthalmic or systemic oral corticosteroids during the study. (i.e., < 2 weeks)
- Prior myopia treatments
- Allergy to atropine or other excipients of the eye drops
- History of amblyopia or strabismus
- History of retinal dystrophy or systemic disorder
- History of glaucoma
- Abnormal ocular biometry aside from axial length
- Employees of the study center and their family members
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The goal of this interventional study is to compare the efficacy of Atropine 0.05% to Atropine 0.5% treatment against progression of axial length in European children with progressive myopia, and to evaluate the safety, adherence, and reasons for nonresponse. Subjects will use Atropine eye drops for a period of 3 years, followed by a 2 year observational period.
The 2 groups in the trial
- Low dose atropineExisting treatment, for comparison
Atropine 0.05% sulphate ophthalmic solution should be administered, one drop in each eye, once daily, at bedtime, for 3 years.
Treatment: Atropine Ophthalmic 0.05%
- High dose atropineExisting treatment, for comparison
Atropine 0.5% sulphate ophthalmic solution should be administered, one drop in each eye, once daily, at bedtime, for 3 years.
Treatment: Atropine Ophthalmic 0.5%
Data and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- Investigator Led, Double-masked, Multicenter, Randomized Clinical Trial for the Comparison of Atropine 0.5% Versus Atropine 0.05% Eye Drops for the Prevention of Myopia Progression in Dutch Children
- Record updated
- 14 September 2026